| Development of AWZ1066S, a Small Molecule Anti-Wolbachia Candidate Macrofilaricide Drug (NCT05084560) | Liverpool School of Tropical Medicine | 2021-12-10 |
| Emodepside Phase II Trial for Treatment of Onchocerciasis (NCT05180461) | Drugs for Neglected Diseases | 2021-08-30 |
| Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-4083 Capsules When Given Alone or In Combination With Albendazole Capsules Moves in The Body of Adult Participants With Onchocerca Volvulus Infection (NCT04913610) | AbbVie | 2021-05-22 |
| Safety and Efficacy of Annual or Biannual Doses of Moxidectin or Ivermectin for Onchocerciasis (NCT03876262) | Medicines Development for Global Health | 2021-05-03 |
| Safety of a Single Dose of Moxidectin Compared With Ivermectin in Individuals Living in Onchocerciasis Endemic Areas and in Individuals Living in Onchocerciasis Endemic Areas With High Levels of Lymphatic Filariasis Co-endemicity Receiving Concomitant Albendazole (NCT04311671) | Medicines Development for Global Health | 2021-05-03 |
| A Pharmacokinetic and Safety Study of Moxidectin to Identify an Optimal Dose for Treatment of Children 4 to 11 Years (NCT03962062) | Medicines Development for Global Health | 2021-03-29 |
| Safety and Efficacy of IDA for Onchocerciasis (NCT04188301) | Washington University School of Medicine | 2019-12-06 |
| Ocular Changes After Ivermectin - (DOLF IVM/Oncho) (NCT03517462) | Washington University School of Medicine | 2018-08-06 |
| Effect of Onchocerciasis Elimination Measures on the Incidence of Epilepsy in Maridi, South Sudan (NCT05750043) | Universiteit Antwerpen | 2018-03-01 |
| Prevalence of LF Infection in Districts Not Included in LF Control Activities (NCT03131401) | Noguchi Memorial Institute for Medical Research | 2018-01-21 |
| Ivermectin Treatment in Patients With Onchocerciasis-associated Epilepsy (NCT03052998) | Robert Colebunders | 2017-10-01 |
| Impact of a Bi-annual CDTI on the Incidence of Epilepsy in an Onchocerciasis-endemic Area (NCT05749653) | Universiteit Antwerpen | 2017-03-01 |
| Clinical Features and Potential Etiology of Epilepsy and Nodding Syndrome in the Mahenge Area, Ulanga District (NCT03653975) | Heidelberg University | 2014-10-01 |
| Efficacy of Ivermectin and Albendazole Against Onchocerciasis in the Volta Region, Ghana (NCT02078024) | University Hospitals Cleveland Medical Center | 2014-06-01 |
| Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis for Ivory Coast (DOLF-Ivory Coast) (NCT02032043) | Washington University School of Medicine | 2014-02-01 |
| IVM Alone vs ALB + IVM Against Onchocerciasis (NCT03238131) | University Hospitals Cleveland Medical Center | 2012-04-01 |
| Mass Drug Administration for Lymphatic Filariasis and Onchocerciasis for Liberia (NCT01905436) | Washington University School of Medicine | 2012-03-01 |
| Pediatric Pharmacokinetics And Safety Study Of Moxidectin (NCT01035619) | Pfizer | 2011-04-01 |
| Study Comparing Moxidectin And Ivermectin In Subjects With Onchocerca Volvulus Infection (NCT00790998) | Medicines Development for Global Health | 2009-04-01 |
| Study Evaluating Orally Administered Moxidectin In Subjects With Onchocerca Volvulus Infection (NCT00300768) | Medicines Development for Global Health | 2006-09-06 |
| Clinical Trial of Rifampin and Azithromycin for the Treatment of River Blindness (NCT00127504) | Centers for Disease Control and Prevention | 2003-07-01 |
| Host Response to Infection and Treatment in Filarial Diseases (NCT00001230) | National Institute of Allergy and Infectious Diseases (NIAID) | 1991-03-15 |